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Selectin blocking activity of a fucosylated chondroitin sulfate
glycosaminoglycan from sea cucumber. Effect on tumor
metastasis and neutrophil recruitment
Abstract
Heparin is an excellent inhibitor of P- and L-selectin binding to the carbohydrate determinant, sialyl
Lewis(x). As a consequence of its anti-selectin activity, heparin attenuates metastasis and inflammation.
Here we show that fucosylated chondroitin sulfate (FucCS), a polysaccharide isolated from sea
cucumber composed of a chondroitin sulfate backbone substituted at the 3-position of the
beta-D-glucuronic acid residues with 2,4-disulfated alpha-L-fucopyranosyl branches, is a potent
inhibitor of P- and L-selectin binding to immobilized sialyl Lewis(x) and LS180 carcinoma cell
attachment to immobilized P- and L-selectins. Inhibition occurs in a concentration-dependent manner.
Furthermore, FucCS was 4-8-fold more potent than heparin in the inhibition of the P- and
L-selectin-sialyl Lewis(x) interactions. No inhibition of E-selectin was observed. FucCS also inhibited
lung colonization by adenocarcinoma MC-38 cells in an experimental metastasis model in mice, as well
as neutrophil recruitment in two models of inflammation (thioglycollate-induced peritonitis and
lipopolysaccharide-induced lung inflammation). Inhibition occurred at a dose that produces no
significant change in plasma activated partial thromboplastin time. Removal of the sulfated fucose
branches on the FucCS abolished the inhibitory effect in vitro and in vivo. Overall, the results suggest
that invertebrate FucCS may be a potential alternative to heparin for blocking metastasis and
inflammatory reactions without the undesirable side effects of anticoagulant heparin.
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Heparin is an excellent inhibitor of P- 
and L-selectin binding to the carbohydrate 
determinant, sialyl Lewisx. As a consequence of 
its anti-selectin activity, heparin attenuates 
metastasis and inflammation. Here we show 
that fucosylated chondroitin sulfate (FucCS), a 
polysaccharide isolated from sea cucumber 
composed of a chondroitin sulfate backbone 
substituted at the 3-position of the β-D-
glucuronic acid residues with 2,4 disulfated α-
L-fucopyranosyl branches, is a potent inhibitor 
of P- and L-selectin binding to immobilized 
sialyl Lewisx and LS180 carcinoma cell 
attachment to immobilized P- and L-selectins. 
Inhibition occurs in a concentration-dependent 
manner. Furthermore, FucCS was 4-8 folds 
more potent than heparin in the inhibition of 
the P- and L-selectin-sialyl Lewisx interactions. 
No inhibition of E-selectin was observed. 
FucCS also inhibited lung colonization by 
adenocarcinoma MC-38 cells in an 
experimental metastasis model in mice, as well 
as neutrophil recruitment in two models of 
inflammation (thioglycollate-induced peritonitis 
and LPS-induced lung inflammation). 
Inhibition occurred at a dose that produces no 
significant change in plasma aPTT. Removal of 
the sulfated fucose branches on the FucCS, 
abolished the inhibitory effect in vitro and in 
vivo. Overall, the results suggest that 
invertebrate FucCS may be a potential 
alternative to heparin for blocking metastasis 
and inflammatory reactions without the 
undesirable side effects of anticoagulant 
heparin. 
 
The surface of carcinoma cells exhibits 
altered glycosylation patterns (1-5), often 
containing highly branched or sialylated 
oligosaccharides, especially fucosylated glycans 
such as sialyl-LewisX (Siaα2-3Galβ1-4(Fucα1-
3)GlcNAc) and sialyl-Lewisa (Siaα2-3Galβ1-
3(Fucα1-4)GlcNAc). The presence of these 
oligosaccharides in tumor cells directly correlates 
with a poor prognosis for cancer patients because 
of tumor progression and metastatic spread (1-5). 
The sLeX-oligosaccharides1 from carcinoma cells 
act as ligands of the 3 members of the selectin 
family of cell adhesion molecules. E-, P- and L-
selectins are vascular receptors for certain normal 
glycoproteins that contain sialyl-Lewisx,a found on 
leukocytes and endothelium (6-8). The selectins 
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also participate in hematogenous metastasis by 
mediating the interactions of tumor cells with 
platelets and endothelium (1-3). Hematogenous 
metastasis occurs through a series of sequential 
events involving the intravasation of tumor cells 
into the bloodstream, evasion of innate immune 
surveillance, adhesion to vascular endothelium of 
distant organs with subsequent extravasation and 
colonization of tissues. It has been proposed that 
these microemboli of tumor cells with platelets 
and leukocytes allows tumor cells to evade the 
immune defenses and eventually colonize distant 
organs, forming metastatic foci (9-15). Several 
studies have shown that a few minutes after 
intravenous injection, tumor cells are detected in 
emboli inside pulmonary capillaries in association 
with platelets and fibrin. 
 Studies from several groups have indicated that 
tumor metastasis in experimental animals is 
inhibited by heparin (16-19). Some clinical studies 
have also shown a beneficial effect of heparin in 
some types of human cancer (20-24). The 
antimetastatic effect of heparin does not reflect its 
anticoagulant activity (25,26), but rather relates to 
heparin’s ability to inhibit the interaction of sialyl 
Lewisx,a-rich oligosaccharides on tumor cells with 
P-selectin on platelets (16,27). In the presence of 
heparin, tumor cells lose the protection conferred 
by platelets becoming susceptible to the 
potentially cytotoxic action of immune effector 
cells, which leads to the inhibition of metastasis. A 
single intravascular injection of heparin promotes 
immediate attenuation of the interaction of tumor 
cells with platelets, resulting in a marked reduction 
of metastasis (16). 
 The recruitment of leukocytes from blood 
to inflamed or injured tissues is also facilitated by 
E-, P- and L-selectins that mediate the initial 
rolling events on activated endothelium (28-29). 
Experiments in vivo show that heparin has a potent 
anti-inflammatory activity, blocking P- and L-
selectins (30). Structural studies indicate that the 
inhibition of L- and P-selectin by heparin requires 
the presence of 6-O-sulfated glucosamine residues 
in the heparin molecule (30).  Subsequent studies 
showed a similar requirement for blocking 
experimental metastasis (31-32). 
 Previously, we isolated a polysaccharide 
from the body wall of the sea cucumber 
Ludwigothurea grisea, which has a backbone like 
mammalian chondroitin sulfate: [4-β-D-GlcA-
1→3-β-D-GalNAc]n, mostly 6-sufated, but 
substituted at the 3-O-position of the glucuronic 
acid residues with 2,4 disulfated α-L-
fucopyranose branches (FucCS) (33,34). The 
sulfated α-L-fucopyranose branches can be 
removed by mild acid hydrolysis giving rise to a 
linear chondroitin sulfate chain (Fig. 1). Some 
fucose units (approximately 25% of the total) 
remain after mild acid hydrolysis, but these are 
mostly non-sulfated residues, which occur as a 
cluster at the reducing end of the polysaccharide 
(34). The sulfated fucose branches resemble 
motifs present in sialyl-Lewis-containing glycans 
of leukocytes and tumor cells that are recognized 
by selectins.  Therefore, we predicted that FucCS 
would inhibit selectin-mediated events, such as 
those observed in tumor metastasis and 
inflammation.  
 In the present study, we evaluated the 
ability of FucCS to block selectin-dependent 
interaction with sialyl-Lewisx-containing ligands 
in vitro and investigate its effect on experimental 
models of metastasis and inflammation in vivo. 
The results show that FucCS is a potent inhibitor 
of P- and L-selectin-mediated interactions. The 
presence of the sulfated fucose branches is a 
fundamental requirement for the inhibitory activity 
of the invertebrate glycan. In addition, animal 
studies indicate that FucCS blocks tumor 
metastasis and reduces neutrophil recruitment to 
inflamed tissues, with only a minor effect on 
anticoagulation. 
 
EXPERIMENTAL PROCEDURES 
 
 Native and chemically modified 
glycosaminoglycans. Porcine intestinal heparin 
(Mr= 12,000-15,000) was kindly provided by 
Patrick Shaklee (Scientific Protein Laboratories 
Inc., Milwaukee, Wisconsin, USA), or obtained 
from Sigma-Aldrich, Saint Louis, MO, USA. 
FucCS was extracted from the body wall of the sea 
cucumber Ludwigothurea grisea freshly collected 
from Guanabara Bay, Rio de Janeiro. The 
extraction and purification procedures were 
carried out as previously described (33-35). 
Removal of the fucose branches from the FucCS 
was performed by mild acid hydrolysis. In these 
experiments, the glycan (50 mg) was dissolved in 
1.0 ml of 150 mM H2SO4, maintained at 100oC for 
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30 min, and the pH of the solution was adjusted to 
7.0 with 0.3 ml of ice-cold 1.0 M NaOH. 
 Detailed structural analysis of the purified 
FucCS and of the product obtained after mild acid 
hydrolysis were performed using 1H-NMR spectra, 
determination of the monosaccharides composition 
and of the sulfate content, analysis of the 
disaccharides formed after digestion with 
chondroitin AC lyase and estimation of the 
molecular size by polyacrylamide gel 
electrophoresis, as previously described (34). 
 FucCS contains GlcUA, GalNH, Fuc and 
sulfate/total sugar on molar ratio of 1.0, 0.9, 1.2 
and 0.7, respectively. Most of the fucose residues 
are removed after mild acid hydrolysis. The molar 
ratio of GlcUA, GalNH, Fuc and sulfate/total 
sugar changes to 1.0, 0.9, 0.3 and 0.6, respectively, 
in this derivative. The small amount of fucose 
units, which resists mild acid hydrolysis, are non- 
sulfated residues occurring as a cluster at the 
reducing terminal of the polysaccharide (34). 
Native FucCS is totally resistant to chondroitin 
AC lyase but after mild acid hydrolysis yields the 
following disaccharides after the action of the 
enzyme: ΔUA-GalNAc4/6diSO4 (12%), ΔUA-
GalNAc6SO4 (53%), ΔUA-GalNAc4SO4 (4%) and 
ΔUA-GalNAc (31%) (see also Ref. 34). 
Comparison of the 1H and 13C-NMR spectra of 
native FucCS and of the product formed after mild 
acid hydrolysis indicates no significant desulfation 
of the central chondroitin sulfate core (34). The 
molecular sizes of the native FucCS and of the 
product formed by mild acid hydrolysis are 40 ad 
8 kDa, respectively, as revealed by polyacrylamide 
gel electrophoresis (34). 
 Mice. C57BL/6 mice (6-8 weeks old) were 
purchased from The Jackson Laboratory (Bar 
Harbor, MA, USA). For the LPS-induced lung 
inflammation experiments, C57BL/6 mice were 
obtained from the Instituto Nacional do Cancer, 
Rio de Janeiro, Brazil. Animals were maintained 
on a 12-hour light-dark cycle, and fed water and 
standard rodent chow ad libitum. All protocols 
were approved by the governmental administration 
of the institutions involved in the work. 
 Binding assays. Inhibition of selectin-sLex 
binding by the glycosaminoglycans was measured 
by coating sterile polystyrene 96-well ELISA 
plates (Corning Inc., Corning, NY, USA) at 4oC 
overnight with 200 ng of polyacrylamide-sLex 
(PAA-sLex; Glycotech Corp., Rockville, MD, 
USA) in 100 µl of 50 mM sodium bicarbonate 
buffer, pH 9.5. Plates were blocked for 3 hours at 
4oC with 200 µl/well of assay buffer containing 20 
mM N-[2-hydroxyethyl] piperazine-N’-[2-
ethanesulfonic acid], pH 7.45, 125 mM NaCl, 2 
mM CaCl2, 2 mM MgCl2, and 1% protease-free 
BSA (Pentex; Miles Inc., Kankakee, IL, USA). 
Recombinant selectin-Ig chimeras were prepared 
as described previously (36) and were 
preincubated at 4oC for about 1 hour with 
peroxidase-conjugated goat anti-human IgG 
(1:1000 dilution in assay buffer, Jackson 
ImmunoResearch Laboratories Inc., West Grove, 
PA, USA). The final selectin-Ig concentrations 
were 2.7, 1.9, and 5.0 µg/ml for E-, L-, and P-
selectin, respectively. The selectin-Ig/secondary 
antibody stock was aliquoted into tubes containing 
heparin, FucCS, buffer alone (positive control), 10 
mM sodium EDTA (negative control), or anti-P-
selectin or anti-E-selectin adhesion-blocking mAb 
(1 µg; Pharmingen, San Diego, CA, USA). The 
solutions (100 µl) were preincubated at 4oC for 30 
minutes and added to ELISA plates. After 4 hours 
at 4oC, the plates were washed three times, 
followed by development with 2 µg/ml O-
phenylenediamine dihydrochloride, 50 mM 
sodium citrate/sodium phosphate buffer, pH 5.2, 
and 0.03% H2O2. After 10 minutes, the peroxidase 
reaction was quenched by adding 50 µl of 4 M 
H2SO4. The absorbance at 490 nm was recorded 
using a microplate reader (Molecular Devices Inc., 
Menlo Park, CA, USA) equipped with SOFTmax 
software. Inclusion of a mAb to P-selectin, E-
selectin of EDTA blocked binding by more than 
90%. All the raw data were converted into 
percentages for comparative purposes using the 
formula: % of maximum = [(average of 
duplicates) – (negative control)]/[(positive control) 
– (negative control)] x 100. 
 Glycosaminoglycan inhibition of LS180 
binding to selectins. The ability of heparin and 
FucCS to inhibit the adhesion of LS180 cells to 
immobilized P-, L- or E-selectins was examined as 
previously described, except that Calcein AM-
loaded LS180 cells (ATCC CL187) were used 
(27). Results are expressed as percent of control 
binding, calculated using the following formula: 
100 (glycan value – EDTA value) / (buffer alone 
value – EDTA value). Each glycan was tested in 
triplicate wells at each relative concentration. 
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 In vivo inhibition of tumor cells-platelet 
interaction by FucCS. MC38 cells stably 
expressing GFP were prepared as described 
previously (16). Mice were intravenously injected 
with heparin (100 units) or FucCS (100 µg) 
followed by injection of 3 x105 of MC-38GFP 
cells 10 minutes later. Lungs were obtained for 
analysis 30 minutes after injection of tumor cells. 
Lung sectioning and staining were performed as 
described (37). To prevent collapse, lungs were 
injected via the trachea with OCT/PBS 1:1 
solution and frozen in OCT compound (Tissue-
Tek, Sakura, Torrance, CA). Frozen lung sections 
were stained with anti-CD41 antibody (Becton 
Dickinson, Mountain View, CA), followed by a 
staining with goat-anti-rat-Alexa 568 conjugated 
antibody (Invitrogen, Carlsbad, CA) and analyzed 
by immunofluorescence microscopy. The extent of 
platelet association with tumor cells was 
quantified by evaluating 20 view fields on 4 lung 
sections by 40x magnification.  
 Metastasis. Mice (6-8 weeks old) were 
intravenously injected with 3 x 105 MC-38-GFP 
tumor cells via the tail vein. Some mice received 
intravenous injection of 50 µg of FucCS or PBS, 
15 minutes prior to tumor cell injection. After 29 
days, mice were anesthetized and perfused with 
PBS. Lungs were macroscopically evaluated for 
metastatic foci and further processed for 
quantification of metastasis by detection of GFP 
fluorescence as described previously (16). Briefly, 
lungs were homogenized in 2 ml of hypotonic 
buffer (20 mM Tris-Cl, pH 7.0) followed by 
addition of Triton X-100 to a final concentration 
of 0.5 %. After 30 min on ice, the insoluble debris 
was sedimented (10,000 x g for 10 minutes), and 
10 µl of supernatant diluted with Tris-Cl buffer 
(20 mM, pH 7.0) to a final volume of 100 µl was 
used for the fluorescence measurement with 
GENios ELISA reader (Tecan, Ex=485 nm and 
Em=535nm). 
 Thioglycollate-induced peritoneal 
inflammation. Mice were injected intraperitoneally 
with 2 ml of 3% thioglycollate broth (lot no. 
54H4607; Sigma-Aldrich) or sterile pyrogen-free 
saline (Gibco BRL; Life Technologies Inc.). Five 
minutes later, the animals received intravenous 
injections of 0.2 ml sterile pyrogen-free saline 
with and without heparin or FucCS (0.2 or 0.5 
mg/mouse). Mice were sacrificed after 3 hours, 
and the peritoneal cavities were lavaged with 8 ml 
of ice-cold PBS containing 3 mM EDTA to 
preventing clotting. Peritoneal cells were counted 
(Coulter Counter; Coulter Corp., Miami, FL, 
USA). The cells were also stained for 30 minutes 
at 4oC with FITC-conjugated rat anti-mouse Gr-1 
mAb (Pharmingen) diluted in PBS containing 
2.5% fetal bovine serum. After washing them 
three times with PBS, neutrophils were quantified 
on FACScan (Becton Dickinson 
Immunocytometry Systems, San Jose, California, 
USA) by gaiting cells expressing a high level of 
Gr-1 antigen (38).  
 LPS-induced lung inflammation. Male 
C57BL/6 mice weighing 20–25 g were injected 
intraperitoneally with 1.5 ml of sterile pyrogen-
free saline with or without 0.25 mg of heparin, 
FucCS or dexamethazone, 1 hour before LPS 
inhalation. The inhalation procedure was 
previously described (39). After 3 hours, airspaces 
were washed with saline to provide 1.5 ml of 
bronchoalveolar lavage fluid (BALF). Total cells 
present in the BALF were counted with a Coulter 
counter ZM (Coulter Electronics, Hialeah, FL, 
USA). Differential cell counts were performed 
after cytocentrifugation (Shandon, East Grinstead, 
UK) and staining with Diff-Quick stain (Baxter 
Dade AG, Dunding, Germany). TNF-α levels 
were determined by a highly specific ELISA with 
a detection limit of 50 pg/ml.  
 Ex-vivo anticoagulant action measured by 
aPTT (activated Partial Thromboplastin Time)- 
To determine the effect of FucCS on coagulation, 
the vena cava was isolated and cannulated with a 
micro catheter (Jelco, Johnson & Johnson Medical 
Inc., USA). Ten minutes after infusion of 100, 200 
or 500 µg of FucCS, blood samples were collected 
by heart puncture into 3.8 % sodium citrate (9:1, 
v/v) for analysis of aPTT.  At least 3 animals were 
used per group. The anticoagulant activity of 
FucCS was expressed as T1/T0, which is the ratio 
between the clotting time in the presence or 
absence of sulfated polysaccharide in the 
incubation.  
 
RESULTS 
 
 FucCS blocks P- and L-selectin-mediated 
binding to sLex. The interaction of FucCS with 
different selectins was evaluated by measuring the 
ability of the glycan to block binding of P-, L- and 
E-selectin-Ig chimeras to immobilized PAA-sLex. 
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Similar to heparin, FucCS inhibited the binding of 
P- and L-selectin-Ig chimeras to PAA-sLex, but 
had no effect on binding to E-selectin-Ig (Fig. 2). 
Inhibition occurred in a dose-dependent manner 
for P- and L-selectin-Ig, and at lower 
concentrations than that of mammalian heparin. 
Analysis of dose-response curves yielded IC50 
values of 0.3 and 2.0 µg/ml for FucCS and heparin 
blocking P-selectin, respectively, whereas the 
corresponding values for blocking L-selectin were 
0.25 and 0.5 µg/ml (Table 1). Removal of the 
sulfated fucose branches completely abolished the 
anti-P-selectin effect (Fig. 2), and also 
significantly reduced the anti-L-selectin effect.
 To determine whether FucCS can block P- 
and L-selectin recognition of mucin-producing 
adenocarcinomas, we tested the inhibitory effect 
of FucCS on tumor cell adhesion to immobilized 
P- or L-selectin-Ig chimeric molecules. FucCS 
inhibited adhesion of LS180 adenocarcinoma cells 
to both mouse P- and L-selectins with an IC50 
value of 10.4 µg/ml (Fig. 3 and Table 1). The 
inhibitory effect of heparin was much less potent 
yielding IC50 values of 40 µg/ml, respectively 
(Fig. 3 and Table 1). No inhibitory effect of 
FucCS or heparin was observed on the binding of 
LS180 cells to mouse E-selectin (data not shown). 
In summary, these data show that FucCS blocks 
both P- and L-selectin mediated interactions with 
sLex and is more potent than heparin.  
 FucCS reduces tumor cell-platelet 
association and prevents lung metastasis. Platelet 
adhesion to tumor cells depends on activation of 
P-selectin expression on platelets, which permits 
binding to sLex containing mucins on the surface 
of tumor cells.  In previous studies, we showed 
that heparin will block this interaction in vitro and 
in vivo (16).  To investigate the potential of FucCS 
to inhibit platelet-tumor cell interactions in vivo, 
FucCS (100 µg) was intravenously injected 30 
minutes before injection of MC-38 mouse 
adenocarcinoma cells. Mice were sacrificed 30 
minutes later and sections of the lungs were 
analyzed for the presence of platelet-tumor cell 
aggregates (Fig. 4). At the doses used, FucCS and 
heparin (100 IU) significantly reduced tumor cell-
platelet association, compared with saline-injected 
mice (Fig. 4). 
 These findings suggested that FucCS 
might also block tumor metastasis.  To investigate 
this possibility, we injected 50 µg of FucCS into 
mice 15 minutes before injection of MC-38 cells. 
After 29 days, mice were sacrificed and the 
dissected lungs were analyzed for the presence of 
metastatic foci by measuring fluorescent GFP-
tagged tumor cells and by counting tumor foci on 
the lung surface. FucCS significantly reduced lung 
metastasis in treated mice compared to the saline-
treated animals by both methods (Fig. 5). Eight of 
nine animals showed a dramatic decrease in the 
number of metastatic foci, supporting the 
assumption that the anti-selectin effect of the 
FucCS correlates with its antimetastatic effect.  
 FucCS prevents neutrophil recruitment in 
vivo. Neutrophil recruitment occurs during acute 
inflammation and depends on both P- and L-
selectins (40,41). To test if FucCS has anti-
inflammatory activity, we examined 
thioglycollate-induced peritonitis, which is 
characterized by neutrophil infiltration into the 
peritoneal cavity. FucCS was injected 
intravenously at doses of 0.2 and 0.5 mg per 
mouse 5 minutes after thioglycollate injection. The 
half-lives of the heparin used (30) and FuCS (not 
published) are about the same (90-120 min). After 
3 hours, when thioglycollate treatment induces 
about 120-fold neutrophil increase, the peritoneal 
cavity was washed with saline and neutrophils in 
the lavage fluid were counted. At the lower dose, 
FucCS inhibited neutrophil recruitment into the 
peritoneal cavity by ~60% compared with control, 
saline-treated animals (Fig. 6A). The same extent 
of inhibition was observed after intravenous 
injection of 0.5 mg of heparin. Increasing the dose 
by 2.5-fold produced further inhibition of 
neutrophil infiltration (p<0.005). Removal of 
sulfated fucose branches completely abolished the 
inhibitory effect of the polysaccharide (Fig. 6A).  
 We also examined neutrophil recruitment 
into the alveolar compartment after inhalation of 
LPS, which induces a frank inflammatory 
response in the lungs. After 3 hours, airspaces 
were washed with saline and the number of 
neutrophils in the BALF was counted.  Infiltration 
of neutrophils into alveolar compartment of LPS-
treated mice was inhibited by 60 % by 
administration of 0.25 mg of FucCS compared 
with saline-treated animals (Fig. 6B). A similar 
inhibitory effect on neutrophil recruitment was 
observed when the animals were treated with the 
same dose of heparin. FucCS had no significant 
inhibitory effect on the production of TNF-α in 
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the alveolar fluid (Fig. 7) indicating that the 
polysaccharide did not affect production of 
inflammatory mediators.  In contrast, treatment 
with dexamethazone, a potent inhibitor of TNF-α 
production by macrophages, significantly reduced 
TNF-α to basal levels (p>0.001). 
 We also assessed the anticoagulant 
activity by aPTT assay of ex vivo plasma, 10 
minutes after intravenous injection of FucCS (Fig. 
8). Doses of 200 and 500 µg/mouse of FucCS 
produced a 1.4- and 2.5-fold increment in the 
plasma activated partial thromboplastin time 
(aPTT), respectively. Administration of 100 µg of 
FucCS only slightly increased aPTT, whereas 
heparin induced a ~9-fold increment. 
 
DISCUSSION 
 
 Several studies have shown that the anti-
selectin activity of heparin accounts for its high 
antimetastatic and anti-inflammatory effects (16-
19,31,32,42). In the present work, we have shown 
that an unique sulfated polysaccharide isolated 
from the body wall of the sea cucumber 
Ludwigothurea grisea is a potent inhibitor of both 
P- and L-selectins. The polymer has a backbone 
like that of mammalian chondroitin sulfate (4-β-D-
GlcA-1→3-β-D-GalNAc)n, mostly 6-sulfated at 
the GalNAc unit, but substituted at the 3-O-
position of the β-D-glucuronic acid residues with 
2,4-disulfated α-L-fucopyranosyl branches (Fig. 
1) (33-34). We provided evidence that the sulfated 
fucose branches are critical for the inhibitory 
activity of the FucCS on P- and L-selectins, 
whereas the sulfated galactosamine residues are 
not relevant. Previous studies indicated that the 
sulfated fucose branches are also required for the 
anticoagulant and antithrombotic activities of 
FucCS (34,35).  
P-selectin glycoprotein ligand-1 (PSGL-
1), a mucin present on the surface of leukocytes, 
binds P-selectin with high affinity (Kd ~ 300 nM) 
(43-48). The interaction is thought to involve two 
main regions in PSGL-1. One region consists of 
three sulfated tyrosine (TyrSO3) residues along 
with a cluster of negatively charged amino acids at 
the N-terminal region of PSGL-1. A second region 
adjacent to the TyrSO3 groups consists of an O-
linked glycan containing sialic acid and fucose 
(sLex).  Together they yield a cooperative binding 
unit with enhanced avidity for P-selectin (49). 
Heparin, with its many sulfate groups including 
those at C6 of the glucosamine units, may 
selectively block the interaction of P-selectin with 
the TyrSO3 cluster. Since FucCS also contains 
sulfate at C6 of the GalNAc units and the length of 
the central disaccharide unit is similar to the 
disaccharide unit in standard heparin (∼10 Å) (50), 
it also could block the interaction of the TyrSO3 
cluster with P-selectin. The sulfated fucose side 
branches in FucCS could enhance its inhibitory 
activity by simultaneously interfering with the 
fucose/sialic acid oligosaccharide-mediated 
interaction.  
Binding studies in vitro revealed that the 
dose of FucCS that inhibits 50% of P- and L-
selectin binding to immobilized PAA-sLex and the 
attachment of LS180 cells to immobilized P- and 
L-selectins is much lower than that of heparin. 
These findings suggested that FucCS may have 
more efficient inhibitory effects on selectin-
mediated events than heparin in vivo. In fact, the 
greater inhibition of platelet-tumor cell 
aggregation in vivo supports this hypothesis (Fig. 
5). Similarly, a 10-fold lower dose of FucCS 
significantly reduced metastasis when compared to 
unfractionated heparin (UFH) (51). Interestingly, 
the anti-selectin effects of FucCS occur at doses 
much lower than that required for anti-
coagulation. Thus, the dose of FucCS to 
significantly elevate the plasma aPTT in mice was 
500 µg, which is 5- and 10-fold higher than that 
required to inhibit platelet-tumor cell association 
and to abolish metastasis in mice, respectively 
(Fig. 8).  Previous studies showed that high doses 
of FucCS, unlike heparin, abolished experimental 
thrombosis in rats without significant change in 
plasma aPTT (35). Thus, the therapeutic index for 
FucCS is much improved compared to heparin, 
which tends to inhibit metastasis and coagulation 
at comparable values (35,43).  
 The results obtained in the two 
experimental models of inflammation 
(thioglycolate-induced peritonitis and the LPS-
induced lung inflammation) showed that FucCS 
inhibited neutrophil recruitment at the time-point 
studied. However, in the thioglycollate model, the 
FucCS was more potent than heparin, whereas in 
the LPS model both compounds showed 
comparable activity. The variation in dose 
response for heparin and FucCS in the two 
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systems could reflect differences in the mode of 
administration (intraperitoneal versus intravenous) 
and subsequent bioavailability or 
pharmacodymanics of the compounds. Although 
FucCS was able to inhibit neutrophil recruitment 
in these models, it did not decrease TNF-α 
production in the LPS model of inflammation, 
indicating that the anti-inflammatory effect of the 
invertebrate glycan involves mainly selectin-
mediated events. 
 It has been reported (43) that the dose of 
UFH required for the anti-selectin effect is very 
close or higher than that needed for the 
anticoagulant action, which increases the 
hemorrhagic risk and makes the clinical use of 
UFH impractical as anti-metastatic and anti-
inflammatory agent. Similarly, the use of low 
molecular weight heparin, which has a much lower 
hemorrhagic effect, is not a good alternative for 
UFH, since it is devoid of significant anti-selectin 
effects (43). Disaccharide primers composed by 
peracetylated GlcNAcβ1,3Gal-naphthalene 
methanol are in preclinical studies as a modified 
agent of Slex structures, that facilitate 
haematogenous metastasis (27), but as far as we 
know, no other heparin mimetics is currently being 
tested as an anti-metastatic agent. In this context, 
FuCS is a better alternative for UFH, since it has a 
higher activity, is devoid of significant bleeding 
effects and could be used without any further 
fractionation after purification. Another important 
aspect to take into account, when proposing the 
use of natural products from mammalian origin as 
therapeutic agents is the risk of contamination 
with pathogens. For example, the association of 
mammalian prion proteins with transmissible 
spongiform encephalopathy has recently restricted 
the use of bovine heparin. Since, heparin is 
obtained exclusively from porcine tissues, the risk 
of contamination with a prion protein or even a 
virus is still present. Based on its potency, better 
therapeutic index, less undesirable side effects, 
natural occurrence, high abundance, and ease of 
purification, intact FuCS could be used as a 
therapeutic agent in the treatment of cancer we 
recommend further testing of intact FucCS as 
potential substitute for heparin.
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1 The abbreviations used are: sLeX, sialyl Lewis x; sLea, sialyl Lewis a FucCS; fucosylated chondroitin 
sulfate; GlcA, glucuronic acid; GalNAc(6SO3), N-acetylgalactosamine bearing a sulfate group on carbon 
6; PAA-sLex, polyacrylamide-sLex; GFP, green fluorescent protein; BALF, bronchoalveolar lavage fluid; 
TNF-α, tumor necrosis factor-alpha; aPTT, activated partial thromboplastin time; PSGL-1, P-selectin 
glycoprotein ligand-1. TyrSO3, sulfated tyrosine; UFH, unfractionated heparin.
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FIGURE LEGENDS 
 
Figure 1: Preponderant structure of the FucCS. The backbone of this glycan is made up by repeating 
disaccharide units of alternating β-D-glucuronic acid  (A) and N-acetyl-β-D-glucosamine (B) the same 
structure as mammalian chondroitin-sulfate. However, in the case of the sea cucumber glycan, the β-D-
glucuronic acid residues bear 2,4-disulfated fucose branches (C) at the 3-O-position. The branches are 
removed by mild acid hydrolysis (arrow). Most of the N-acetyl-β-D-galactosamine are 6-sufated (53%), 
however small amounts of 4,6-disulfated (12%), 4-sulfated (4%) and non-sulfated (31%) are also found. 
Some fucose units (approximately 25% of the total) resist to mild acid hydrolysis, but these are mostly 
non-sulfated residues, which occur as a cluster at the reducing end of the polysaccharide (not shown in the 
Panel, see Ref. 34). 
 
Figure 2: Inhibition of selectin-Ig binding to immobilized PAA-sLex. Inhibition curves were obtained 
using FucCS (filled circles), heparin (filled squares) and de-fucosylated FucCS (deFucCS, open circles) 
(see methods). Each point represents the average of duplicate determinations, and the data are 
representative of three separate experiments. The points are the average value ± SEM. 
 
Figure 3: Inhibition of LS180 cell binding to selectins. Adhesion of LS180 cells to immobilized selectin 
chimeras was measured in the presence of increasing concentrations of FucCS (filled circles) or heparin 
(open circles) (see methods). Each point represents the average of triplicate experiments, and the data are 
representative of three separate experiments. 
 
Figure 4: In vivo inhibition of MC-38 cells-platelet interaction. Heparin (100 IU) or FucCS (100µg) was 
intravenously injected followed by an injection of MC-38GFP cells (see Methods). Platelet interactions 
with injected cells were evaluated in lungs from mice terminated 30 min after injection. Quantification of 
platelet-tumor cell interaction from 3 independent experiments. Horizontal bars represents medians, boxes 
represent percentiles 25 and 75, and vertical bars represents ranges. The observed differences were 
statistical significant as determined by one way ANOVA analysis (p< 0.01). 
 
Figure 5: FucCS eliminates experimental metastasis. FucCS (50 µg) was intravenously injected followed 
by injection of 3 x 105 MC-38-GFP tumor cells 15 minutes later (see Methods). Mice were terminated 
after 29 days. Dissected lungs were further macroscopically evaluated for the presence of metastatic foci 
(A) and processed for quantification of metastasis by detection of GFP fluorescence (B). Representative 
examples of dissected lungs from mice injected with FucCS or with PBS (C). Statistical significance was 
determined by Student's t-test (p< 0.001). 
 
Figure 6: Inhibition of neutrophil recruitment. (A) Thioglycollate-induced peritoneal inflammation. 
Heparin (0.5 mg/mouse), FucCS (0.2 or 0.5 mg/mouse) or de-fucosylated FucCS (deFucCS, 0.5 
mg/mouse) were injected intravenously 5 minutes after thioglycollate was injected intraperitoneally. The 
number of Gr-1-positive granulocytes in the peritoneal cavity was quantified after 3 hours (see Methods). 
Significant difference in neutrophil counts: in the control mice that received PBS versus those injected 
with the indicated glycans (*); in mice injected with 0.5 mg of heparin or 0.2 mg of FucCS versus those 
injected with 0.5 mg of FucCS (**); and in mice injected with 0.5 mg of heparin or 0.2 mg of FucCS 
versus those injected with 0.5 mg of deFucCS (***) was determined. (B) LPS-induced lung 
inflammation. Heparin or FucCS (0.25 mg/mouse) were injected intraperitoneally 1 hour before LPS 
inhalation. After 3 hours, neutrophils were isolated and counted as described in Methods. *Significant 
difference in neutrophil counts in the control mice that received PBS versus those injected with the 
indicated glycans. Each bar represents the average value ± SD; N = 6. Statistical significance was 
determined by Student's t-test (p< 0.001). 
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Figure 7: Inhibition of TNF-α production in LPS-induced lung inflammation. Heparin, FucCS or 
dexamethazone (Dexa) (0.25 mg) were injected intraperitoneally 1 hour before LPS inhalation. After 3 
hours, TNF-α levels were determined by a highly specific ELISA assay. *Significant difference in the 
concentration of TNF-α in the bronchoalveolar fluid of control mice that received PBS versus those that 
inhaled LPS and/or were injected with FucCS. ** Significant difference in the concentration of TNF-α in 
the bronchoalveolar fluid of control mice that inhaled LPS and were injected with FucCS versus those 
that inhaled LPS and were injected with dexamethazone. Each bar represents the average value ± SD; N = 
6. Statistical significance was determined by Student's t-test (p< 0.001). 
 
Figure 8: Dose dependence for ex vivo anticoagulant action of FucCS. Ex vivo anticoagulant effects of 
different doses of FucCS (--) or heparin (--) were determined by the activated partial thromboplastin 
time (aPTT) assays of ex vivo mouse plasma before (T0) and 30 minutes (T1) after intravascular 
administration of FucCS. Each point represents the average ± SD of triplicate experiments, and the data 
are representative of three separate experiments. T0 = 22.1 ± 0.3 seconds. Conversion factor to convert 
T1/To into IU/mg = 0.53. 
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Table 1: Anticoagulant and inhibitory properties of heparin and FucCS 
___________________________________________________________________________________ 
 
Glycan 
 
aPTT 
(IU/mg) 
Inhibition of 
Selectin-PAA-sLex Binding 
(IC50, µg/ml) 
Inhibition of Tumor 
Cell-selectin Adhesion 
(IC50, µg/ml) 
___________________________________________________________________________________ 
  P-selectin L-selectin P-selectin L-selectin 
  ___________________________ ________________________ 
Heparin 193 2.0 0.5 40 40 
FucCS 40a 0.3 0.25 10.4 10.4 
___________________________________________________________________________________ 
a Value obtained from reference 34. 
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FIGURE 1 
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FIGURE 2 
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FIGURE 3 
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FIGURE 4 
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FIGURE 5 
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FIGURE 6 
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FIGURE 7 
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FIGURE 8 
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